Molecular events and cytotoxic effects of a novel thiosemicarbazone derivative in human leukemia and lymphoma cell lines

• Published in: Hematology/oncology and stem cell therapy Vol. 14; no. 1; pp. 51 - 64
• Main Authors: Santos-Pirath, Íris Mattos, Walter, Laura Otto, Maioral, Mariana Franzoni, Pacheco, Lucas Antônio, Sens, Larissa, Nunes, Ricardo José, Santos-Silva, Maria Cláudia
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.03.2021
• Subjects: Anticancer activity; Apoptosis; Cytotoxicity; Lymphoid neoplasms; Thiosemicarbazone derivative; Lymphoid neoplasms; Cytotoxicity; Thiosemicarbazone derivative; Anticancer activity; Apoptosis
• ISSN: 1658-3876
• DOI: 10.1016/j.hemonc.2020.07.007

The present study aimed to investigate the cytotoxic effect of 38 new thiosemicarbazone derivatives on hematological neoplastic cells lines and to select the most effective compounds to investigate the main molecular mechanisms involved in cell death. Cytotoxicity screening on Daudi and Jurkat cells revealed that only compound 1b met the selection criteria; therefore, it was chosen for further investigation. Cell viability of Daudi, Jurkat, Molt-4, Namalwa, K562, and MM.1S cell lines decreased in a concentration- and time-dependent manner after compound1b incubation; nevertheless the compound neither caused significant hemolysis nor reduction in peripheral blood mononuclear cell viability. Although no changes were observed on cell cycle or Ki-67 expression, compound1b induced apoptotic-like cell death with mitochondrial involvement, Bax/Bcl-2 inversion, AIF release, survivin inhibition, and caspase-3 activation in both Daudi and Jurkat cells. Furthermore, the compound reduced NFκB expression in Jurkat cells. In Daudi cells, compound1b also decreased CHOP, Akt, pAkt, and MAPK/ERK2 expression, thereby suggesting modulation of UPR, PI3K/Akt/mTOR, and MAPK/ERK signaling pathways. Finally, the compound was able to reduce the cell viability of samples collected from patients with different lymphoid neoplasms subtypes, showing that thiosemicarbazones derivatives could be used in the development of new drugs with anticancer activity.